Get started
IDEAYA Biosciences, Inc.IDEAYA Biosciences, Inc.IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IDYA chart


Full chart

IDYA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.59 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.33 USD
Net income (FY)
‪−112.96 M‬ USD
Revenue (FY)
‪23.39 M‬ USD
Shares float
‪76.56 M‬
Beta (1Y)
1.69

Employees


Employees (FY)
124
Change (1Y)
+21 +20.39%
Revenue / Employee (1Y)
‪188.59 K‬ USD
Net income / Employee (1Y)
‪−910.98 K‬ USD

About IDEAYA Biosciences, Inc.


Sector
Health Technology
CEO
Yujiro S. Hata
Headquarters
South San Francisco
Website
ideayabio.com
Founded
2015
FIGI
BBG00CTZ4D83
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

IDYA news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where IDYA is featured.

See all sparks 

Frequently Asked Questions


The current price of IDYA is 31.28 USD — it has decreased by −1.38% in the past 24 hours. Watch IDEAYA Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange IDEAYA Biosciences, Inc. stocks are traded under the ticker IDYA.
IDYA stock has risen by 2.53% compared to the previous week, the month change is a 1.49% rise, over the last year IDEAYA Biosciences, Inc. has showed a 1.13% increase.
We've gathered analysts' opinions on IDEAYA Biosciences, Inc. future price: according to them, IDYA price has a max estimate of 65.00 USD and a min estimate of 27.00 USD. Watch IDYA chart and read a more detailed IDEAYA Biosciences, Inc. stock forecast: see what analysts think of IDEAYA Biosciences, Inc. and suggest that you do with its stocks.
IDYA reached its all-time high on Feb 15, 2024 with the price of 47.74 USD, and its all-time low was 2.95 USD and was reached on Mar 17, 2020. View more price dynamics on IDYA chart.
See other stocks reaching their highest and lowest prices.
IDYA stock is 5.56% volatile and has beta coefficient of 1.69. Track IDEAYA Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is IDEAYA Biosciences, Inc. there?
Today IDEAYA Biosciences, Inc. has the market capitalization of ‪2.53 B‬, it has increased by 0.89% over the last week.
Yes, you can track IDEAYA Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
IDEAYA Biosciences, Inc. is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
IDYA earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.65 USD resulting in a 7.36% surprise. The estimated earnings for the next quarter are −0.63 USD per share. See more details about IDEAYA Biosciences, Inc. earnings.
IDEAYA Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪4.27 M‬ USD. In the next quarter, revenue is expected to reach ‪5.47 M‬ USD.
IDYA net income for the last quarter is ‪−51.82 M‬ USD, while the quarter before that showed ‪−52.77 M‬ USD of net income which accounts for 1.80% change. Track more IDEAYA Biosciences, Inc. financial stats to get the full picture.
No, IDYA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 124.00 employees. See our rating of the largest employees — is IDEAYA Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IDEAYA Biosciences, Inc. EBITDA is ‪−220.54 M‬ USD, and current EBITDA margin is −557.71%. See more stats in IDEAYA Biosciences, Inc. financial statements.
Like other stocks, IDYA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IDEAYA Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IDEAYA Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IDEAYA Biosciences, Inc. stock shows the neutral signal. See more of IDEAYA Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.